---
title: "羅氏的 III 期 evERA 研究數據顯示，giredestrant 顯著提高了 ER 陽性晚期乳腺癌患者的無進展生存期"
description: "巴塞爾，2025 年 10 月 18 日- 羅氏（SIX: RO, ROG. OTCQX: RHHBY）今天宣佈了 III 期 evERA 乳腺癌研究的積極結果。數據顯示，giredestrant 與依維莫司聯合使用顯著降低了疾病進展或死亡的風險（無進展生存期）"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/261705568.md"
published_at: "2025-10-18T06:02:39.000Z"
---

# 羅氏的 III 期 evERA 研究數據顯示，giredestrant 顯著提高了 ER 陽性晚期乳腺癌患者的無進展生存期

> 巴塞爾，2025 年 10 月 18 日- 羅氏（SIX: RO, ROG. OTCQX: RHHBY）今天宣佈了 III 期 evERA 乳腺癌研究的積極結果。數據顯示，giredestrant 與依維莫司聯合使用顯著降低了疾病進展或死亡的風險（無進展生存期）

Basel, 18 October 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today positive results from the phase III evERA Breast Cancer study. Data showed giredestrant in combination with everolimus significantly reduced the risk of disease progression or death ( progression-free survival.

### Related Stocks

- [RHHBY.US - 羅氏(ADR)](https://longbridge.com/zh-HK/quote/RHHBY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Roche Appoints Mark Dawson As New Head Of Roche Pharma Research And Early Development | Roche Holding AG :ROCHE HOLDING AG - APPOINTMENT OF MARK DAWSON, M.D., PH.D., AS NEW HEAD OF ROCHE PHARMA RESEARCH AND E | [Link](https://longbridge.com/zh-HK/news/276097246.md) |
| Roche's Gazyva Meets Main Goal in Late-stage Kidney Disease Study | Roche's Gazyva Meets Main Goal in Late-stage Kidney Disease Study | [Link](https://longbridge.com/zh-HK/news/276037536.md) |
| Maine CDC reports 4 additional cases of measles have been confirmed in Maine | Maine CDC reports 4 additional cases of measles have been confirmed in Maine | [Link](https://longbridge.com/zh-HK/news/276164223.md) |
| Genentech Reports Positive Phase III Results For Gazyva In Primary Membranous Nephropathy | Genentech, part of the Roche Group, announced positive Phase III results for Gazyva in treating primary membranous nephr | [Link](https://longbridge.com/zh-HK/news/276037337.md) |
| Roche Says Its Blood Cancer Drug Shows Positive Results in Trial | Roche announced that its blood cancer drug Gazyva/Gazyvaro has shown positive results in a late-stage trial for patients | [Link](https://longbridge.com/zh-HK/news/276037735.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。